Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNPX OTCMKTS:LTUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.58-1.5%$0.86$0.42▼$55.00$6.47M-0.98403,679 shs1.60 million shsLTUSLotus Pharmaceuticals$0.00$0.00$0.00▼$0.01$11.64M-1.684,528 shs10,000 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex0.00%-8.93%-28.47%-68.99%-96.14%LTUSLotus Pharmaceuticals0.00%+25.71%+22.22%+22.22%-38.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.58-1.5%$0.86$0.42▼$55.00$6.47M-0.98403,679 shs1.60 million shsLTUSLotus Pharmaceuticals$0.00$0.00$0.00▼$0.01$11.64M-1.684,528 shs10,000 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex0.00%-8.93%-28.47%-68.99%-96.14%LTUSLotus Pharmaceuticals0.00%+25.71%+22.22%+22.22%-38.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNPXGenprex 1.00SellN/AN/ALTUSLotus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GNPX and LTUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNPXGenprexN/AN/AN/AN/A$2.42 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNPXGenprex-$16.23M-$14.14N/AN/AN/AN/A-247.32%-176.73%9/2/2026 (Estimated)LTUSLotus Pharmaceuticals-$30KN/AN/AN/AN/AN/AN/AN/AN/ALatest GNPX and LTUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNPXGenprexN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNPXGenprexN/A5.615.61LTUSLotus PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNPXGenprex14.05%LTUSLotus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGNPXGenprex0.25%LTUSLotus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNPXGenprex2010.93 million10.90 millionNo DataLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableGNPX and LTUS HeadlinesRecent News About These CompaniesLotus Pharmaceuticals Inc.March 31, 2026 | barrons.comLotus Pharma partners with Formycon on biosimilar of KeytrudaFebruary 11, 2026 | thepharmaletter.comTGlenmark Specialty S.A. and Lotus International Pte. Ltd. enter into exclusive licensing agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and VietnamJanuary 15, 2026 | aninews.inAInnobic buys Alvogen PharmaDecember 7, 2025 | bangkokpost.comBLENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South ...December 1, 2025 | caledonianrecord.comCBoryung Acquires Taxotere Global Business to Expand into 19 CountriesOctober 29, 2025 | msn.comAvalo Therapeutics completes enrollment in Phase 2 LOTUS trialOctober 29, 2025 | msn.comAvalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for ...October 29, 2025 | caledonianrecord.comCRx Rundown: Genmab, Novartis, AstraZeneca and moreOctober 2, 2025 | mmm-online.comMAlvogen Pharma announces sale to Lotus Pharmaceutical, creating a leading global specialized generics platformSeptember 25, 2025 | pharmabiz.comPAlvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics PlatformSeptember 23, 2025 | finance.yahoo.comTwin Lotus: 52 Years of Herbal Innovation Goes GlobalSeptember 22, 2025 | khaosodenglish.comKPhase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett SyndromeSeptember 15, 2025 | appliedclinicaltrialsonline.comAAcadia Pharmaceuticals publishes interim LOTUS study data in journalSeptember 12, 2025 | msn.comReal World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental ...September 12, 2025 | finance.yahoo.comPTT to sell stake in Taiwan pharmaceuticals firmJuly 25, 2025 | msn.comSamarsh Capital, Vyom Partners, Blue Lotus Lead INR 50 Cr Investment in Sai ParenteralsJuly 8, 2025 | msn.comGeely’s Lotus says ‘no plans’ to close any factoryJuly 2, 2025 | msn.comLotus Pharmaceutical Co Ltd (1795) - Investing.com UKJune 26, 2025 | uk.investing.comLotus Therapeutics Appoints Leslie Felix as Chief Growth OfficerJune 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX and LTUS Company DescriptionsGenprex NASDAQ:GNPX$0.58 -0.01 (-1.52%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$0.57 -0.01 (-1.72%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0044 0.00 (0.00%) As of 06/18/2026 03:38 PM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
